secwatch.observer — SEC 8-K summary
======================================

Issuer:     InMed Pharmaceuticals Inc. (INM)
CIK:        0001728328
Form:       8-K
Filed at:   2024-11-05T23:59:59+00:00
Accession:  0001213900-24-094349
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 3.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

InMed Pharmaceuticals granted Nasdaq exception until Dec 2; plans 1-for-20 reverse stock split
--------------------------------------------------------------------------------

- Nasdaq Panel grants InMed exception to Dec 2, 2024 to show $1 bid price compliance for 10 consecutive trading days.
- Board approved 1-for-20 reverse stock split on Oct 29, 2024; shares would reduce from ~14.36M to ~718k.
- Reverse split requires no shareholder action; fractional shares not issued; trading symbol INM unchanged.
- Company must evidence compliance by Dec 2; no assurance of regaining compliance by that date.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1728328/000121390024094349/0001213900-24-094349-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1728328/000121390024094349/ea0220029-8k_inmed.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-094349

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer